EY: Buyers Need To Fill Revenue Gaps But M&A Targets May Be Scarce

In its Beyond Borders 2024 report, coinciding with the start of the BIO meeting, EY analysts see declining revenues for big pharma, which could be addressed by M&A, if the right takeouts exist.

Bridging Gap
EY expects pharma companies to look to M&A to fill revenue gaps

In its Beyond Borders 2024 report, issued in tandem with the start of this year’s BIO International Convention, EY analysts said the biopharmaceutical industry appeared to turn a corner in late 2023 with strong dealmaking activity that has continued into 2024, generating optimism that financing for smaller and less established companies will improve.

More from BIO

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Sutro Works Toward A Better Ovarian Cancer ADC

 
• By 

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

 
• By 

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

 
• By 

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

More from Conferences

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

Reflections From Biotech Leader John Maraganore

 

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.

M&A Takeoff May Be Delayed, Experts Predict

 

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.